In a pioneering move for precision diagnostics in tier 2 and 3 cities, HCG Manavata Cancer Centre (HCGMCC) has partnered with health-tech innovator Qure.ai to deploy advanced AI-powered imaging solutions for early detection and structured management of lung diseases, including suspected lung cancer.
Under this collaboration, qXR (AI-enabled Chest X-ray) and qCT (AI-enabled Chest CT) will be deployed at the hospital, supported by qTrack, Qure.ai’s disease tracking platform. These solutions enable real-time risk identification, automated triaging, and faster, more accurate diagnoses. The initiative is part of Qure.ai’s ongoing partnership with Johnson & Johnson MedTech, aimed at democratizing lung health across India.
“A 5 mm nodule missed today becomes stage-four cancer tomorrow. Qure.ai’s AI acts as our 24/7 digital sentinel catching whispers of disease before symptoms scream,” said Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director, KIMS Manavata Hospitals, HCGMCC & Six Sigma, Nashik.
HCGMCC has also launched a dedicated Incidental Pulmonary Nodule (IPN) Clinic, positioning itself as a central hub for structured follow-up, early intervention, and improved patient outcomes in lung health.
Beyond AI adoption, HCGMCC has made significant strides including a breakthrough blood test capable of detecting 30 cancers with 98.4% accuracy, and the establishment of a Centre of Excellence in Cell and Gene Therapy, bringing CAR-T cell therapy and other next-gen treatments to non-metro cities.
“Our mission is to make the most advanced cancer care accessible across regions, bringing AI, robotics, and future-ready oncology to patients today,” added Dr. Nagarkar.